The Development of a Bimodal Walking-Running Prosthetic Foot

项目总结/摘要 在为期两年的第二阶段工作中，解放技术公司（Liberating Technologies，Inc.）(LTI)，沿着其合作者 Fillauer Companies和Hanger Clinic将改进、扩展和测试双峰步行跑步脚，该脚将 然后准备成为一个可行的商业产品，可以根据现有的L代码报销 报销结构。该项目的目标是创建一个单一的脚，在每种模式下进行优化， 与处于步行模式时的步行脚和处于跑步模式时的跑步脚相当。这只新奇的脚 将为下肢截肢者提供目前无法获得跑步的脚， 保险范围，参加跑步和其他跑步活动的机会（例如篮球， 等等）。来增强体质。在这样做的过程中，凯撒脚也将允许增加社会 参与和与这些活动相关的身心健康益处。 为了实现这一目标，我们将通过实现 本文的研究目标如下：（1）对双模态足的设计方案进行优化设计，实现功能齐全的样机 准备好进行测试，（2）执行验证测试以确认原型符合设计标准，（3）验证 原型在试点带回家试验，并评估其对下肢截肢者的身体活动的影响， (4)开始准备向食品药品管理局提交凯撒足的申请 结果将是在实验室和真实的世界中验证和确认双峰足装置的数据。 该产品将是一种高度先进的、商业上可行的、经过验证和确认的双模态假足。这 创新的设计使我们能够解决两个已确定的主要障碍，阻止LLAs参与 这些活动：1）设计不当的假肢（通过提供具有优化设计、对准的脚， 步行和跑步模式下的生物力学）和2）缺乏高活动度假体的可及性 (the脚的费用将由保险支付）。

PROJECT SUMMARY / ABSTRACT Over the course of this two-year Phase II effort, Liberating Technologies, Inc. (LTI), along with its collaborators at Fillauer Companies and Hanger Clinic, will refine, expand, and test a bimodal walking-running foot that would then be poised to become a viable commercial product that can be reimbursed under the existing L-code reimbursement structure. The goal of this project is to create a single foot that is optimized in each mode and comparable to a walking foot when in a walking mode and a running foot when in running mode. This novel foot would provide lower limb amputees who don’t currently have the access to running feet due to the lack of insurance coverage, the opportunity to participate in running and other running-based activities (e.g. basketball, etc.) to increase physical fitness. In doing so, the Caesar foot would also allow for the increased social participation and the physical and mental health benefits that are associated with these activities. In order to achieve this goal, we will progress and refine the bimodal foot technology with the achievement of the following objectives: (1) iterate and optimize the design of the bimodal foot to achieve a fully functional prototype ready for testing, (2) perform verification testing to confirm the prototype meets the design criteria, (3) validate the prototype in a pilot take-home trial and assess its impact on the physical activity of lower limb amputees, and (4) start preparing for an FDA submission for the Caesar foot. The outcomes will be data that verify and validate the bimodal foot device in the laboratory and in the real world. The product will be a highly advanced, commercially viable, verified, and validated bimodal prosthetic foot. This innovative design allows us to address both of the identified primary barriers preventing LLAs from taking part in these activities: 1) inadequately designed prostheses (by providing a foot with optimized design, alignment, and biomechanics in both walking and running modes) and 2) the lack of accessibility for higher activity prostheses (the cost of the foot would be covered by insurance).